Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 250 entries
View as:

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT06776510 Org: User:
Start: 01/15/25 End: 06/01/25 Due: 06/01/26

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT04008888 Org: User:
Start: 01/05/18 End: 08/01/20 Due: 08/01/21

A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT06792630 Org: User:
Start: 01/31/25 End: 11/30/26 Due: 11/30/27

Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

Phase: N/A Priority: Normal
NCT ID: NCT06931912 Org: User:
Start: 12/01/24 End: 11/30/26 Due: 11/30/27

Anti-CD38 Antibody Treating Evans Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06014775 Org: User:
Start: 12/01/23 End: 08/31/25 Due: 08/31/26

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05958719 Org: User:
Start: 03/02/23 End: 03/02/27 Due: 03/02/28

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT06716658 Org: User:
Start: 12/15/24 End: 11/15/28 Due: 11/15/29

Herombopag for Chemotherapy-induced Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05236582 Org: User:
Start: 03/14/22 End: 12/31/25 Due: 12/31/26

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Phase: N/A Priority: Normal
NCT ID: NCT05523128 Org: User:
Start: 09/29/22 End: 10/31/25 Due: 10/31/26

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Phase: N/A Priority: Normal
NCT ID: NCT06793475 Org: User:
Start: 03/31/25 End: 12/31/26 Due: 12/31/27

Anti-CD38 Antibody Treating Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT06838962 Org: User:
Start: 08/01/24 End: 08/31/26 Due: 08/31/27

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Phase: N/A Priority: Normal
NCT ID: NCT04226950 Org: User:
Start: 01/10/20 End: 11/20/24 Due: 11/20/25

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Phase: N/A Priority: Normal
NCT ID: NCT05583838 Org: User:
Start: 11/22/22 End: 07/16/24 Due: 07/16/25

Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03165851 Org: User:
Start: 04/10/05 End: 12/31/15 Due: 12/31/16

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05562882 Org: User:
Start: 12/10/22 End: 12/31/25 Due: 12/31/26

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase: N/A Priority: Normal
NCT ID: NCT06586099 Org: User:
Start: 10/05/24 End: 06/01/25 Due: 06/01/26

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06570915 Org: User:
Start: 12/01/25 End: 09/01/28 Due: 09/01/29

Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

Phase: N/A Priority: Normal
NCT ID: NCT06992076 Org: User:
Start: 02/01/26 End: 12/31/28 Due: 12/31/29

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

Phase: N/A Priority: Normal
NCT ID: NCT06991920 Org: User:
Start: 09/30/25 End: 04/01/32 Due: 04/01/33

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Phase: N/A Priority: Normal
NCT ID: NCT06992128 Org: User:
Start: 05/22/25 End: 08/31/28 Due: 08/31/29

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Phase: N/A Priority: Normal
NCT ID: NCT06387121 Org: User:
Start: 04/02/24 End: 12/31/28 Due: 12/31/29

Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

Phase: N/A Priority: Normal
NCT ID: NCT06918834 Org: User:
Start: 04/01/25 End: 04/01/28 Due: 04/01/29

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05335226 Org: User:
Start: 06/06/22 End: 03/01/24 Due: 03/01/25

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03029338 Org: User:
Start: 06/08/17 End: 06/22/21 Due: 06/22/22

National Longitudinal Cohort of Hematological Diseases

Phase: N/A Priority: Normal
NCT ID: NCT04645199 Org: User:
Start: 12/01/20 End: 12/01/30 Due: 12/01/31